TY - JOUR
T1 - Composition, cytotoxic and antimicrobial activities of Satureja intermedia C.A.Mey essential oil
AU - Sharifi-Rad, Javad
AU - Sharifi-Rad, Mehdi
AU - Hoseini-Alfatemi, Seyedeh Mahsan
AU - Iriti, Marcello
AU - Sharifi-Rad, Majid
AU - Sharifi-Rad, Marzieh
N1 - Publisher Copyright:
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2015/8/3
Y1 - 2015/8/3
N2 - In this study, the essential oil (EO) constituents from the aerial parts of Satureja intermedia C.A.Mey were detected by GC and GC/MS. The antimicrobial activity of EO on oral pathogens and its cytotoxicity to human cancer cells were determined by the microbroth dilution method and the crystal violet staining method, respectively. Thirty-nine compounds were identified and the main EO constituents were γ-terpinene (37.1%), thymol (30.2%), p-cymene (16.2%), limonene (3.9%), α-terpinene (3.3%), myrcene (2.5%), germacrene B (1.4%), elemicine (1.1%) and carvacrol (0.5%). The S. intermedia EO showed a concentration-dependent decrease in viability of Hep-G2 (hepatocellular carcinoma) and MCF-7 (breast adenocarcinoma) human cancer cell lines (p < 0.05). Antimicrobial screening of S. intermedia EO demonstrated slight antibacterial and antifungal activities against Streptococcus mutants, S. salivarius, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and C. glabrata. Further preclinical studies are needed to assess the efficacy and safety of S. intermedia EO as a new promising anticancer agent.
AB - In this study, the essential oil (EO) constituents from the aerial parts of Satureja intermedia C.A.Mey were detected by GC and GC/MS. The antimicrobial activity of EO on oral pathogens and its cytotoxicity to human cancer cells were determined by the microbroth dilution method and the crystal violet staining method, respectively. Thirty-nine compounds were identified and the main EO constituents were γ-terpinene (37.1%), thymol (30.2%), p-cymene (16.2%), limonene (3.9%), α-terpinene (3.3%), myrcene (2.5%), germacrene B (1.4%), elemicine (1.1%) and carvacrol (0.5%). The S. intermedia EO showed a concentration-dependent decrease in viability of Hep-G2 (hepatocellular carcinoma) and MCF-7 (breast adenocarcinoma) human cancer cell lines (p < 0.05). Antimicrobial screening of S. intermedia EO demonstrated slight antibacterial and antifungal activities against Streptococcus mutants, S. salivarius, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and C. glabrata. Further preclinical studies are needed to assess the efficacy and safety of S. intermedia EO as a new promising anticancer agent.
KW - Breast adenocarcinoma
KW - GC/MS
KW - Hepatocellular carcinoma
KW - Human cancer cells
KW - Oral pathogens
UR - https://www.scopus.com/pages/publications/84938892203
U2 - 10.3390/ijms160817812
DO - 10.3390/ijms160817812
M3 - Artículo
C2 - 26247936
AN - SCOPUS:84938892203
SN - 1661-6596
VL - 16
SP - 17812
EP - 17825
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 8
ER -